Alector has completed subject enrolment in the 76-week, randomised, Phase II PROGRESS-AD trial, which is assessing the ...

Single and multi-dose studies of the small molecule TREM2 agonist VG-3927 clear early safety hurdle. Meanwhile, new findings ...

It binds both transmembrane and soluble TREM2, triggering a rise in CSF sTREM2. Single and multi-dose studies of the small ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild ...

Eisai Europe Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted Leqembi® (lecanemab) Marketing Authorisation (MA) in the European Union (EU).1 This makes the medicine ...

In the landmark Amgen v. Sanofi case (previously covered here), the Supreme Court affirmed that patent claims drawn to a genus of ...

The inclusion of optional targets and exclusion of Scope 3 emissions in the Science Based Targets initiative’s (SBTi) draft update to its Corporate Net-Zero Standard could hinder investment in CO2 ...

Antibody molecules, or “immunoglobulins”, have been recognized only in vertebrates and all are found to have a fundamentally similar structure consisting of two heavy and two light peptide ...

The granted claims cover the novel design and therapeutic applications of bispecific antibodies that simultaneously inhibit CHI3L1 and PD1, key targets implicated in immune evasion by tumor cells.

But promising results from a recent clinical trial suggest that broadly neutralizing antibody therapy (bNAbs) may be able to accomplish the next best thing. Data from the trial—a collaboration ...